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Background: Different mechanisms will be activated during ischemic stroke. Calpain
proteases play a pivotal role in neuronal death after ischemia damage through
apoptosis. Anti-apoptotic activities of the oxytocin (OT) in different ischemic tissues
were reported in previous studies. Recently, a limited number of studies have noted
the protective effects of OT in the brain. In the present study, the neuroprotective
potential of OT in an animal model of transient middle cerebral artery occlusion
(tMCAO) and the possible role of calpain-1 in the penumbra region were assessed.
Methods: Adult male Wistar rats underwent 1 hour of tMCAO and were treated
with nasal administration of OT. After 24 hours of reperfusion, infarct size was
evaluated by triphenyltetrazolium chloride. Immunohistochemical staining and
Western blotting were used to examine the expression of calpain-1. Nissl stain-
ing was performed for brain tissue morphology evaluation. Results: OT reduced
the infarct volume of the cerebral cortex and striatum compared with the isch-
emia control group significantly (P < .05). Calpain-1 overexpression, which was
caused by ischemia, decreased after OT administration (P < .05). The number of
pyknotic nuclei in neurons increased dramatically in the ischemic area and OT
attenuated the apoptosis of neurons in the penumbra region (P < .01). Conclusion:
We provided evidence for the neuroprotective role of OT after tMCAO through
calpain-1 attenuation. Key Words: Stroke—tMCAO—calpain-1—oxytocin.
© 2018 National Stroke Association. Published by Elsevier Inc. All rights reserved.
Introduction
Stroke is a devastating neurological condition and the
second leading cause of death in the world.1-3 The 2 main
types of strokes are ischemic and hemorrhagic, and isch-
emic stroke is more common.4 Delayed neuronal death
often occurs after ischemic insult from a few hours to
days following stroke onset, which provides a wide ther-
apeutic window.5 Use of tissue plasminogen activator such
as intravenous alteplase is the only treatment with proven
efficacy in patients with ischemic stroke6; however, this
treatment has a time limit of 4.5 hours after the onset of
symptoms and in some cases have contraindications.7 Neu-
ronal injury in stroke is caused by different mechanisms,
including excitotoxicity, inflammation, oxidative stress, and
apoptosis.8,9 One of the dramatic events during ischemia
is the increase in intracellular calcium (Ca+2), which leads
to the activation of calpain proteases.5 Two major isoforms
of calpains, calpain-1 and calpain-2, are differently sen-
sitive to the amount of calcium required for their activation.
Calpain-1 (µ-calpain) and calpain-2 (m-calpain) are acti-
vated by approximately 50 µM and approximately 1 mM
of calcium concentrations, respectively.10 Once activated
in the cytoplasm of neurons, calpain degrades cytoskel-
eton elements, leading to the promotion of neuronal
apoptosis.5,11 The role of calpain-1 in the neuronal apoptosis
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in response to various stimulatory conditions has been
known. Research shows that calpain-1 increases reac-
tive oxygen species levels and inflammatory cytokines.12
Because of the molecular complexity process13 and clin-
ical importance of penumbra region management after
brain ischemia, the neuroprotection is needed.14 The oxy-
tocin hormone (OT) is a small peptide with 9 amino acids.
OT is synthesized mainly by paraventricular and supra-
optic nuclei in the hypothalamus and its receptors are
present in many parts of the brain on the neuronal mem-
brane, in the cytoplasm, around the nucleus, and within
the nucleus.15,16 Recently, it has been shown that OT plays
an important role in many pathological conditions fol-
lowing ischemia–reperfusion in various regions, including
the bladder and cardiomyocytes, and ovarian, liver, and
renal tissue. Studies have indicated that the protective
effects of OT are related to its anti-inflammatory, anti-
apoptotic, and antioxidant properties.17-23
Moreover, some recent data suggest that OT has also
neuroprotective effects in both males and females, including
social neuroprotection, oxygen–glucose deprivation re-
sistance, immune system modulation, and anti-apoptotic
and anti-inflammatory functions.24-29 Altogether, the pro-
tective role of OT in pathological conditions has turned
it into an attractive candidate for improving the outcomes
after cerebral ischemia. However, the neuroprotective effects
of OT on cerebral stroke and related signaling pathways
are not completely understood. In this study the effect
of OT on the ischemic brain and the potential of calpain-1
protease as a hallmark in apoptosis were examined.
Materials and Methods
Ethical Statement
All the experiments were approved by the ethics com-
mittee of Kashan University of Medical Sciences (Reference
number: IR.KAUUMC.REC.1394.21) and conducted ac-
cording to the Guide for the Care and Use of Laboratory
Animals.
Animals
Because endogenous OT may influence the severity of
infarction, male rats are preferable. Thirty Wistar rats weigh-
ing 200-300 g (3-4 months old) were used in this
experiment. The animals were kept in air-conditioned
rooms in a controlled environment at 21 ± 2°C with sea-
sonal lighting conditions (12 hours of light and 12 hours
of darkness); food and water were freely available during
the experiment. The rats were randomly divided into 4
groups: (1) sham group; (2) ischemia/reperfusion (I/R)
group; (3) IR + OT 20 µL group; and (4) IR + OT 40 µL
group. The animals received a single dose of OT hormone
after transient middle cerebral artery occlusion (tMCAO)
through nasal administration and were sacrificed 24 hours
after I/R.
Transient Focal Cerebral Ischemia
The rats were anesthetized with 3% isoflurane in
conjunction with oxygen (Eickemeyer, Germany) first in
a chamber, and they remained in this state with 2%
isoflurane through a nose cone. Incision in the scalp
was made along midline to find the bregma point. The
skull was thinned bilaterally 4-5 mm outside and 1-2 mm
posterior the bregma; laser Doppler probes (Moor In-
struments, VMS-LDF2, Axminster, UK) were then fixed
in thinned locations. Each animal was placed in supine
position at 37 ± .5°C on a warm pad (Narco Bio-Systems,
Houston, TX). Midline skin incision was performed with
a 3-cm length in the neck to expose the left carotid
sheath. The left common carotid artery (CCA) is charily
separated from the vagus nerve and was blocked to
stop the backflow of blood. The bifurcation of CCA into
the external carotid artery and internal carotid artery
was blocked temporarily with a microclip. Then a small
incision was made in the wall of CCA (in 5-mm bifur-
cation) by microscissors. The nylon monofilament with
a silicone-coated tip (Doccol, USA) entered into the
artery lumen and moved slowly forward until a sudden
decrease pertains to the base flow (Fig 1, A). In this
condition, the left middle cerebral artery blood flow is
barred through the circle of Willis. Animals were kept
anesthetized in the ischemic state for 1 hour, and middle
cerebral artery (MCA) territory blood flow was recorded
every 10 minutes. After 1 hour, the intraluminal mono-
filament was withdrawn slowly and the artery was
ligated. In this situation blood flow returned to the
base values, which is defined as reperfusion.
Hormone Therapy
Hormone administration was done immediately after
I/R. OT drug from sigma (Cat. Number 06379) was pro-
vided and mixed with sterile Ringer’s solution.30 Hormone
therapy was done for 2 groups with doses of 20 and 40 µg.
Since OT could rapidly access the brain following intra-
nasal administration, the nasal path was used to investigate
the effects of OT.31 In detail, 20 µL solution with differ-
ent doses was used bilaterally on the rhinarium. The
rhinarium refers to the glabrous skin circa, the nostrils
that have a large number of free nerve endings. Using
the tip of a 100-µL pipette, the total volume of 20 µL was
divided similarly and allowed to spread in the squa-
mous epithelium of both sides of the rhinarium for
2 minutes. According to this method, OT increases in the
brain and plasma following intranasal administration after
only 30-60 minutes at a dose of 20 µL.31
Behavioral Testing
The Garcia test for evaluating the behavioral aspects
of stroke was performed in a blinded manner 24 hours
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after stroke.32 The rats were given different scores through
a series of tests, including spontaneous activity and
walking, and observing symmetry in limb movement,
ability to climb, body proprioception, and response to vi-
brissae touch. In these tests, the minimum and maximum
scores were 3 and 18, respectively. Statistical analysis was
performed by Mann–Whitney test by comparing the
groups.
Infarct Volumes
Triphenyltetrazolium chloride (TTC) staining was used
to evaluate the infarct volume. The animals were anes-
thetized by 10% chloral hydrate (500 mg/kg body,
intraperitoneal) 24 hours after tMCAO induction. The brain
was removed after decapitation and was placed in a Brain
Matrix (Zivic Instruments, USA) in a freezer for 4 minutes
to tighten the soft brain tissue. The brain was sliced into
6 coronal slices in with a thickness of 2 mm. The brain
sections were shacked for 10 minutes at 37°C in 1% TTC
solution in phosphate-buffered saline. Nonischemic areas
turned deep red, whereas damaged areas remained col-
orless. The sections were arranged from anterior to posterior
in a petri dish serially; images of the brain slices were
taken by a digital camera with nice separability (Canon,
Ohta-ku, Tokyo, Japan); and the stained brain sections
were scannedwith ImageJ program (version 1.44p, Bethesda,
Maryland, USA). Sections were preserved in −80°C for
further experiments. The infarct volume in the cerebral
cortex (Cx) and striatum (St) region were measured sep-
arately (Fig 1, B,C). Total infarct volume was calculated
by adding the mean area of each section and multiplied
by the thickness of the sections (Fig 1, D).33
RNA Isolation and Real-Time PCR
The isolation of total RNA from the penumbra region
of samples was carried out with AccuZol reagent (Bioneer,
Daedeok-gu, Daejeon, Korea) and transcribed to com-
plementary DNA (cDNA) using iScript Reverse
Transcription Supermix (Bio-Rad, Germany), also the cDNA
were diluted 1:10 after serial dilutions were made. Primer3
online software was applied to design polymerase chain
reaction (PCR) primers, and annealing temperatures were
determined using gradient PCR. In this study, the fol-
lowing primers were used: oxytocin receptor (OTR)
forward: 5’CTGGCTTTTGTCCCTTTCCC3’ and OTR
reverse: 5’TTCCCAGTGCTTTCCAGGAT3. Real-time
reverse transcription-PCR reaction was performed in a
reaction mixture consisting of 5 µL of master mix (Bio-
Rad), 2 µL of water, .5 µL of each primer (10 µM stock),
and 2 µL of diluted cDNA. The results were calculated
of the ratio between the amount of target gene and the
amount of hypoxanthine phosphoribosyltransferase. The
Figure 1. rCBF measurement of MCA perfusion territory and volumetry of infarct region. (A) Laser Doppler was used for monitoring relative rCBF of
MCA in the ipsilateral hemisphere during surgery. rCBF decrease is shown as percentage of baseline value. (B) A central core of severe infarction endan-
gered after ischemia, surrounded by damaged brain tissue but viable and potentially salvageable (penumbra: P). Core infarct volume of rat brains obtained
24 hours after tMCAO with TTC staining. The noninfarct areas which still have metabolism reaction with TTC and produced red stain and dead infarct
tissue appears white. (C) Two images of TTC-stained sections are representative of the different groups. (D) Quantitative analysis of infarct volume. OT
treatment reduced the infarct volume relative to the I/R group in both St (*P ≤ .05) and Cx (#P < .05) following ischemia. Abbreviations: Cx, cortex;
MCA, middle cerebral artery; OT, oxytocin; rCBF, regional cerebral blood flow; St, striatum; tMCAO, transient middle cerebral artery occlusion; TTC,
triphenyltetrazolium chloride. (Color version of figure is available online.)
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relative changes were analyzed using the ΔΔCT method
as previously described.34
Tissue Fixation and Immunohistochemistry
The animals were profoundly anesthetized with 10%
chloral hydrate (500 mg/kg body, intraperitoneal) 24 hours
after tMCAO. Animals were perfused transcardially first
by 50 mL of normal saline solution (.9% NaCl) and then
by 250 mL of NBF fixative solution (10% neutral buff-
ered formalin, pH = 7). Brains were carefully dissected
out and kept in the same fixative solution for another
48 hours at room temperature. After processing, brains
were embedded in paraffin wax. The brains were then
sectioned at a thickness of 5 µm by a microtome (Diapath,
Martinengo, Italy), and sections of forebrain were placed
on silane-coated glass slides. These slides were
deparaffinized and rehydrated. Before antibody incuba-
tion, antigen unmasking was performed in preheated .1 M
citrate buffer (pH = 6). Sections were blocked with a block-
ing solution obtained from kit (UltraTek HRP Anti-
Polyvalent, ScyTek Laboratories, Logan, USA) to prevent
nonspecific binding of the antibody for 7 minutes at room
temperature. Blocking solution was removed and each
section was incubated with calpain-1 primary antibody
(ab28258, Abcam, Germany) at 1:100 dilution in a humid
chamber for 90 minutes. The endogenous peroxidase ac-
tivity was blocked using 10% hydrogen peroxide–
methanol for 10 minutes at room temperature. After
washing, sections were incubated with a secondary an-
tibody (Anti-Polyvalent Biotinylated Antibody, ScyTek) and
then with horseradish peroxidase in a humid chamber
for 10 minutes. Visualization occurred after the reaction
with diaminobenzidine. Coverslips were mounted on sec-
tions and the slides were examined by a Nikon microscope
(Nikon Eclipse Ti-U, Hokkaido, Japan). Calpain–1-
positive cells were counted and calculated as number of
cells per mm2.35
Western Blotting
The penumbra region of ischemic tissues was taken out
and homogenized. After protein quantification, 80 µg of
total protein was loaded from each sample. Using sodium
dodecyl sulfate polyacrylamide gel (10% gel), proteins were
separated by molecular weight and transferred onto
polyvinylidene difluoride papers using a semidry trans-
fer method. The membranes were blocked in 5% skim
milk for 1 hour and incubated with primary antibodies
against β-actin (abcam, 1:5000) and calpain-1 (abcam, 1:2000)
at 4°C overnight. After washing, blots were incubated for
1 hour with horseradish peroxidase–conjugated second-
ary antibody (abcam, 1:3000). Protein bands were
illuminated using Clarity western enhanced chemilumi-
nescence substrate kit (BioRad) and visualized on x-ray
films. Images were analyzed through densitometry soft-
ware (ImageJ version 1.44).
Cresyl Violet (Nissl) Staining
For cresyl violet staining, 5-µm coronal sections were
used. Deparaffinized and rehydrated tissue sections were
stained with .1% cresyl violet solution for 10 minutes. His-
tological changes were observed by a light microscope
(Nikon Eclipse Ti-U) and counted by the Camera Control
Unit DS-L2 software. Neuronal count and survival (normal
or pyknotic nuclei) in Nissl-stained sections was pre-
sented as cells per mm2 and estimated as follows: (number
of surviving neurons/total number of neurons) × 100.
Nitrate Analysis
Griess reagent was applied for nitrite measurement.36
Reduction of nitrate to nitrite was done using vana-
dium chloride (VCl3). Tissue lysates were precipitated with
trichloroacetic acid (10%). After that, supernatants were
collected and used for nitric oxide (NO) measurement.
One hundred microliters of each sample and standard
(0-100 µM) was pipetted into a 96-well plate. One hundred
microliters of VCl3 was added to each well and then mixed
with 50 µL of 2% sulfanilamide and 50 µL of .1% N-(1-
Naphthyl) ethylenediamine dihydrochloride. Plate was
incubated at 37°C for 45 minutes. Absorption was read
at a wavelength of 540 nm and concentrations were cal-
culated using the gained standard curve.
Statistical Analysis
In this study, a total of 30 rats were used. Seventeen
of them were used for western blot and Nitrate analysis
and 13 were subjected to perfusion and immunohisto-
chemistry (IHC) or Nissl staining. SPSS software (version
16.0) was used for data analysis. The one-way analysis
of variance and Tukey post hoc tests for the difference
among the groups were applied, except for behavioral
analysis. In this study, a P value of less than .05 was con-
sidered statistically significant.
Results
Cerebral Blood Flow Measurement
Laser Doppler monitoring was used to ensure a suc-
cessful blockage of MCA. Laser Doppler measurement
indicated that in all rats, regional cerebral blood flow values
dropped at least more than 55% compared with peri-
ischemic basal values significantly after tMCAO induction.
Values should also remain stable during MCA occlu-
sion (Fig 1, A). Regional cerebral blood flow values showed
no significant differences among the groups.
Assessment of Neurological Function
Behavioral aspects of tMCAO were evaluated in each
rat 24 hours after ischemic induction in a blinded manner.
Sham-operated animals without tMCAO showed a
maximum score of 18 points. The ischemia group showed
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sensory–motor deficiency, and a better behavioral con-
dition was observed in all hormone-treated groups,
although these data were not statistically significant (Fig 2).
Effects of Oxytocin on the Infarct Volume
The extent of brain damage after tMCAO was deter-
mined by evaluating the infarct volume. All animals were
sacrificed 24 hours after surgery. TTC-stained brain sec-
tions for analysis of infarct volume were examined
throughout the ipsilateral Cx and St. Representative TTC-
stained brains of the various groups are illustrated in
Figure 1, C. All hormone-treated IR/OT 20 and IR/OT
40 groups showed a significant reduction of the infarct
region in both St and Cx compared with the I/R group
(P < .05) (Fig 1, D).
Expression of OTR mRNA
We used real-time PCR to observe the effect of tMCAO
on OTR expression in the penumbra region and possi-
ble effects of OT on them. The OTR mRNA level in I/R
was significantly increased in comparison with control
(P < .01). The effect of OT treatment on levels of OTR
mRNAs was examined 24 hours after I/R, and the
hormone-treated IR/OT 20 and IR/OT 40 groups were
significantly decreased in comparison with the I/R group
(P < .01) (Fig 3).
Effects of Oxytocin on Calpain-1 Activation
The expression of calpain-1 protease was evaluated by
IHC and Western blot technique (Fig 4). In the ischemia
group, the penumbra region of the ipsilateral hemi-
sphere revealed a significant increase in the number of
calpain–1-positive cells compared with the contralateral
hemisphere (control group). Treatment by OT could de-
crease the calpain–1-positive cells compared with the
ischemia group significantly (*P < .05) (Fig 4, B). IHC results
were confirmed with immunoblot analysis with a prom-
inent elevation in the levels of calpain-1 (76 kDa fragment)
protease after ischemia induction that is attenuated by
hormone therapy (*P < .05) (Fig 4, C,D).
Effects of Oxytocin on Neuronal Damage
The number of Nissl-stained cells and also neuronal
vacuolation and nuclear pyknosis were evaluated and com-
pared. Figure 5 shows representative examples of Nissl
staining in the contralateral hemisphere (control group)
and the ipsilateral hemisphere (ischemia group) by light
microscopic evaluations. In the hormone-treated IR/OT
20 and IR/OT 40 groups, the number of injured neurons
after ischemia was significantly lower than in the control
group (**P < .01).
Effects of Oxytocin on Nitric Oxide Metabolites
Considering that the short half-life of NO makes NO
measurement difficult, we evaluated NO metabolites,
namely nitrite and nitrate (NOx), which are more stable.
The level of NOx in brain tissue can be an indicator of
NO production in the region. The concentration of NOx
was increased in the ischemic hemisphere compared with
that in the nonischemic hemisphere. However, there was
no significant change in the levels of NOx in the groups
treated with 20 µg and 40 µg OT compared with the isch-
emia group (I/R) (Fig 6).
Discussion
Our study indicated that the protective effect of OT
in ischemic stroke may be associated with calpain–1-
dependent mechanisms. Ischemic stroke is the most
common cause of adult neurological disorder and 1 of
10 causes of the global burden of disease and prema-
ture death worldwide. Therefore, understanding how the
brain responds to damage in addition to recovery pro-
cesses after stroke will provide insight into prevention
and new therapeutic strategies.37-39 Neuroprotective effects
Figure 2. Neurological behavior score. Garcia test scores in the sham group
and I/R, I/R + OT 20, and I/R + OT 40 groups were not significant. Ab-
breviations: I/R, ischemia–reperfusion; OT 20, oxytocin 20 µg; OT 40, oxytocin
40 µg.
Figure 3. RT-PCR analysis of OTR gene expression after cerebral isch-
emia. Ischemia significantly increased the expression of OTR (P < .01) and
treatment of oxytocin significantly reduced it (P < .01). Abbreviations: I/R,
ischemia–reperfusion; OT 20, oxytocin 20 µg; OT 40, oxytocin 40 µg RT-
PCR, reverse transcription polymerase chain reaction.
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Figure 4. Calpain-1 analysis after focal cerebral ischemia. Calpain-1 protein was evaluated by IHC and western blot analysis. (A) Photomicrographs of
IHC staining of rat brain after ischemia using a polyclonal antibody against calpain-1. The quantity of calpain-positive cells in Cx is shown in (B). The
increased number of calpain–1-positive neurons decreased after oxytocin treatment (*P < .05). (C) Photomicrographs of Western blot analysis in Cx (pen-
umbral zone). β-actin (43 kDa) was used as a loading control for analysis of calpain-1 (76 kDa). (D) Densitometry determination was determined by
densitometry of calpain-1 band. *P < .05; **P < .01. Abbreviations: Cx, cortex; IHC, immunohistochemistry; I/R, ischemia–reperfusion; OT 20, oxytocin
20 µg; OT 40, oxytocin 40 µg. (Color version of figure is available online.)
Figure 5. Nissl staining after focal cerebral ischemia. (A) Photomicrographs of Nissl staining of the brain Cx in the control group and I/R, I/R + OT 20,
and I/R + OT 40 groups. Black arrows indicate nuclear pyknosis and arrowheads show neuronal vacuolation as a result of MCAO in the ispilateral hemi-
sphere, which is differentiated from intact neurons in the contralateral hemisphere of the same region with a pale and round nucleus and a prominent
nucleolus (white arrows). (B) Neuronal survival rate in the penumbra decreased in animals treated with OT compared with the I/R group (**P < .01).
Abbreviations: Cx, cortex; I/R, ischemia–reperfusion; MCAO, middle cerebral artery occlusion; OT 20, oxytocin 20 µg; OT 40, oxytocin 40 µg. (Color
version of figure is available online.)
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of OT and the underlying molecular mechanisms are under
discussion after different ischemia–reperfusion models.17-23
Our aim here is to investigate the protective effect of OT
in a tMCAO rat model and its possible protective mecha-
nisms by investigating calpain expression in the brain.
Determination of infarct size is the primary measure
to find out the outcome of ischemia.28 Our findings show
a significant interaction between OT treatment and infarct
size (Fig 1). Infarct regions were significantly decreased
after 20 µg and 40 µg OT nasal administrations. So far,
there have been some reports of reduction in infarct size
following treatment with OT after ischemia. Jankowski
et al reported that treatment with OT after cardiac isch-
emic induction in rat can reduce myocardial infarct size
and improve heart function.40 A single research noted that
the effects of the OT hormone after cerebral ischemia im-
proved social neuroprotection. Karelina et al concluded
that endogenous increase in OT level could decrease infarct
size.27 Different mechanisms such as regulating and bal-
ancing of anti-inflammatory and proinflammatory cytokines
have been considered as the cause of decreasing infarct
volume after OT treatment.40
Our findings have shown significant changes in the
infarct volume, although no significant difference was found
among behavioral variables (Fig 2). These results are con-
sistent with the findings of Desland et al, which is likely
due to the small number of animals in their study (n = 6).41
It is well known that ischemia causes an increase in
inflammatory response.42 Although Szeto et al showed that
in vitro modeling of lipopolysaccharide-induced inflam-
mation, OTR expression increases,43 for the first time, the
present study reports that OTR expression increases after
cerebral ischemia. Several studies have indicated that OT
has anti-inflammatory activity.22,44 Here, we observed a
decrease in OTR gene expression after OT treatment in
the peri-infarct area, which seems to be due to the anti-
inflammatory activity of OT.
Our results show a significant decrease in calpain-1 ex-
pression after OT administration in the tMCAO model
(Fig 4). High levels of glutamate and excessive activation
of glutamate receptors (N-methyl-D-aspartate, Amino-3-
hydroxy-5-methyl-4-isoxazole propionic acid, and kainate
receptors) lead to influx of Ca2+ through these receptors
immediately after the ischemic insult.45 Influx of calcium
into cells known as a signaling cascade, with overactivation
of Ca2+-dependent proteases such as calpain-1, is located
mainly in the neuronal cell bodies and dendrites. OT plays
a key role in neurons. The presence of OTRs has been
shown in several brain regions, such as the bed nucleus
of the stria terminalis, lateral septum, anterior olfactory
nucleus, pyriform cortex, olfactory bulbs, amygdale,
and hippocampus.46 Indeed, neurons express OTRs in all
brain regions.47 OT decreases the number of functional
glutamatergic synapses at the cellular level and the ac-
tivity of N-methyl-D-aspartate receptors, inhibiting release
of the main excitatory amino acids such as glutamate and
glutamate activation.48-50 This might be related to the ability
of OT in decreased expression of calpain. As we reported
previously, the activity of calpain-1 protease in neurons
following focal ischemia causes neural apoptosis.35 Apop-
tosis occurs through 2 pathways in cerebral ischemia:
mitochondrial (intrinsic pathway) and the activation of
death receptors (extrinsic pathway). In the intrinsic apoptotic
pathway, an increase in the intracellular Ca2+ level leads
to overactivation of calpain proteases.51 This pathway is
initiated by cleavage of Bid to truncated Bid (tBid), which
leads to conformational changes in the other proapoptotic
members such as Bak, Bax, Bad, and BclXS; extracellular
release of cytochrome c; activation of caspase-3; and finally
DNAdamage and apoptosis.52 Previous studies have shown
that pretreatment with OT after cardiac ischemia insert a
protection by reducing Bax and p53 gene expression
and increasing Bcl-2.53,54 It has also been supposed that
pretreatment with OT in ischemia could provide
neuroprotection through TypeAgamma-aminobutyric acid
receptors modulation.25 Type A gamma-aminobutyric acid
receptors—major inhibitory neurotransmitter receptors in
the central nervous system—are downregulated after isch-
emia in in vitro conditions and causes calpain-dependent
neuronal apoptosis.55 By and large, these data suggest that
OT administration has a protective role following the isch-
emia induction in different organs.17-23 Our study confirms
the beneficial effects of OT treatment in the brain after
ischemia by preventing calpain overexpression.
Previous studies have indicated that the involvement
of NO after the stroke leads to the activation of calpain
and caspase-3.56,57 On the other hand, a beneficial effect
of NO has been shown in some studies through the release
of NO. After determining the neuroprotective effect of
OT through calpain-1 regulation, we examined the role
of OT in NOx production.20,58 Our findings indicate that
treatment with 20 µg and 40 µg doses do not change the
level of NO production (Fig 6). Our findings seem to be
Figure 6. Levels of NOx after focal cerebral ischemia. The ischemic hemi-
sphere had higher NOx concentrations compared with the nonischemic
hemisphere. No significant differences were found between the OT-treated
animals and the ischemia group (I/R). Abbreviations: I/R, ischemia–
reperfusion; NOx, nitrite and nitrate; OT 20, oxytocin 20 µg; OT 40, oxytocin
40 µg.
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consistent with the results of other studies that showed
OT function depends on its dose.59-61
Biochemical events such as apoptosis, oxidative stress,
and inflammatory reaction occur during ischemia–
reperfusion and lead to permanent injury of proteins, DNA,
and cellular organelles that eventually causes the death
of neurons.51 Markers other than Nissl staining are
commonly used for the detection of neuronal cell death.62
Calpain has been implicated in cell death processes, and
inhibition of calpain provides neuroprotection.63 In this
study, many neurons in the I/R group showed an aberrant
morphology, including shrunken cell bodies and nuclear
pyknosis. OT treatment improved morphology damage
in neurons (Fig 5). This refers to the neuroprotective role
of OT, which could result in the inhibition of calpain.
Overall, these findings will add to our knowledge of
the positive effects of OT on the outcomes of stroke. There
is a need for further research to ascertain which factors
are involved in OT-induced interactions during or after
ischemic stroke.
Conclusion
OT could have an important role in protecting neurons
against cerebral ischemia. However, little attention has
been paid to the mechanisms of OT action after isch-
emia. This study confirms that the protective effect of OT
is associated with calpain–1-dependent apoptotic pathway.
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